COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

By | January 9, 2023
In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.